Item 5. Other Information
ITEM 5.
OTHER INFORMATION
None.
18
ITEM 6.
EXHIBITS
EXHIBIT INDEX
Incorporated by Reference Herein
Exhibit
Number
Description
Form
Date
3.1
Amended and Restated Certificate of Incorporation of Phio Pharmaceuticals
Corp.
Current Report on Form 8-K (File No. 001-36304)
November 19, 2018
3.2
Certificate of Amendment to the Amendment and Restated Certificate
of Incorporation of Phio Pharmaceuticals Corp.
Current Report on Form 8-K (File No. 001-36304)
January 14, 2020
3.3
Certificate of Amendment to the Amendment and Restated Certificate
of Incorporation of Phio Pharmaceuticals Corp.
Current Report on Form 8-K (File No. 001-36304)
January 25, 2023
3.4
Certificate of Designation of Series D Preferred Stock, dated November
16, 2022.
Current Report on Form 8-K (File No. 001-36304)
November 16, 2022
10.1
Employment Agreement, dated February 20, 2023, by and between the Company
and Robert J. Bitterman.
Current Report on Form 8-K (File No. 001-36304)
February 22, 2023
31.1
Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer and Principal Financial Officer . *
32.1
Sarbanes-Oxley Act Section 906 Certification of Principal Executive Officer and Principal Financial Officer. **
101.INS
Inline XBRL Instance Document.*
101.SCH
Inline XBRL Taxonomy Extension Schema Document.*
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document.*
104
The cover page for this report, formatted in Inline XBRL (included in Exhibit 101).*
*
Filed herewith.
**
Furnished herewith and not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section or incorporated by reference into any filing under the Securities Act or the Exchange Act.
19
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Phio Pharmaceuticals Corp.
By:
/s/ Robert J. Bitterman
Robert J. Bitterman
President and Chief Executive Officer
(as Principal Executive and Financial Officer)
Date: May 11, 2023
20
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.